Member Info for sadoldgit

Sneckieboy since you have a degree you should be able to research.
What are your concerns is it the low SP or the unlikely event that 1801 will not be progressed?
Sareum on contract will have been made an assurance that all in vivo work will be carried out to GLP.

However if this is all Sareum have submitted it may well prove that this is not enough.

In light of current reports of non compliance all The MHRA are doing is making sure that the CRO they have used is compliant.

Tell me that a reputable CRO is not going to be able to provide evidence of compliance.

What is your degree in Sneckieboy ?

Regards

The good thing with good constructive debate.
Remember that I stated that not had the Ethics review meeting. You made very valid opinion of that would be done early on. I looked through several pieces with Ethics rewiew meeting and in fact you were correct in your summise. I were wrong but the end result was the producing of a flow chart. They are both undertaken at the same time. Makes sense what is is the chart and of course validates your correctness of thinking.

As it stands Sareum have 14 days to address issues of required supportive information and reply. They may ask for additional time and I see no reason for this to be granted.

All the MHRA are doing is their job that the data that Sareum have supplied has been performed to good laboratory practice.

It should not be a problem with end result of acceptance as using in effect a non biased result.

What I believe has happened is large pharma use their own inhouse testing which may come under scrutiny especially now that poor GLP has been identified in the US, Russia and the UK.

In effect the data provided has been evidenced to manipulation in favour of the owners of the drug commercialisation .

It is common now for a pharma to pick up a drug in commercial use and add further indications. No problem as such but since covid the governing bodies have not carried out sufficient audits or investigations to ensure adequate compliance.

The CRO contracted to carry out our research will be completely unbiased. However, due to recent reports will mean these companies go through the same scrutiny that will now be applied to the big pharma.

What will apply to one will apply to the rest.

Big pharmas have paid big multi billion pound compensation claims in the past for illegal activities. A leopard does not change it spots over night.

I really do look in the absence of good news Circle of lifes opinions on the value of the company.

Nothing produced by this alleged investor apart from sheer tripe. The new poster that has been here years and all of a sudden becomes judgemental and at the same time makes a poor attempt to curry favour in his oh so patronising ways.

I have been here too long and seen many in the same guise. The only difference is that the later ones are more cunning.
They are not fools. But they think we are. Read deeply into his posts and try to realise his objectives and aims.

They will hit a balanced BB and drive wedges in. Yes we all have our beliefs and are entitled to them.

But I will not accept an argument connived, from an unsubstantiated opinion from others that compromise my belief in the considerable investment I have in Sareum.

My belief is that circle of lifes posting days are somewhat limited.

Regards and keep the faith.

Good after noon HbD.
I will be back. Nice to spend a few days away. I notice that circle of life did not take long to show his face after he thought the coast was clear.

Got a couple of questions for him/her.

Circle of life who are these people that rip PI's off. that you are calling wa****s ?
I have drawn the conclusion from the nature of the posts that you have aimed this not to undermine but to insult me.
Have you aimed this insult to me or or not?
A simple yes or no will suffice.
If it is a 'no' then who is it aimed at?
If no one here then what is the point of posting?

Another thing out of general.interest is what attracted you to becoming invested and how long ago was this?

You have only ever posted about thirty something posts since you claim to be invested here. Not much at all.

one more thing.
A poster stated that we are all entitled to change our minds which l agree with 100%. However, no one has the right to change mine.

Like yourself CoL l do have job. Mobile phones not allowed where l work. Longish hours and 700 miles from home but does pay me circa 100k a year.

Look forward to some interesting chats with you very soon.

Regards

Star 786 i have never written anything regards to AGM apart from attendance and non attendance. Fact.

Bluenose your posts from July. Very bullish and anti negative posts.

Not a dreamer. I am an investor in a company I researched and believe will be prove to be a good investment but will also benefit people who are suffering a wide range of different illnesses/ conditions. If you think differently a) why are you invested if indeed you are? b) why are you posting if you’re not an investor or have no belief in Sar?

28th July 22 price 192.5p
Cobaltblue why do posters like you p…on people’s parade??? This is excellent news a great RNS demonstrating where we are heading yet you somehow see a negative. Only the share price doubling might have brought a slight smirk from you… give it up if it’s an instant share price explosion you’re after. I got my jam today with the RNS and will add more at the present price because I’m convinced

What’s the point in moaning Warthog you’ve been here long enough you know the script. If you’re a LTH you’ll have made a Bob or two . Never a get rich quick with SAR but the patient have already been rewarded. It’s sell up or wait , patience is all that’s required.

Then we get recently

Seriously Over- opinionated Guy still spreading the love on here I see. His way or the highway . He’ll say he’ll listen to other opinions but his posts say otherwise. It’s sit and wait time as no one outside of the company actually knows what’s they have to do regarding the CTA. Meanwhile Seriously Over-opinionated Guy will pass his opinion on timescales and the information requested for the CTA as fact. No matter how long it may take I think I’ll wait for Sareum to produce the facts . I apologise for taking up some space that SOG would see as reserved for him.

if anyone is up to their neck it looks like you Bluenose. Buying at 192.5!
You change your tune to suit your agenda as proven by your above posts.

I am invested long term. Hence still have the faith in the science. I will take the rough with the smooth. Capitalise now on low SP. I see positive when people like yourself see negative and take advantage.

I am here until on -licence at least and am in the position to add as when I feel. Why would I ever feel the need to be negative.?

Regards

Star786.

More speculation about the AGM. It will just be a rubber stamping, no information divulged and no questions answered that they don't want to.
Take a cold shower, we will know nothing more by 16th December.
Legally they had to hold this AGM despite what SOG and Potnak had been trying to spread disinformation.
Get real. Get voting to show your disapproval of the BOD.

Please indicate to us where i have 'been trying to spread disinformation regarding the AGM.

Citizen 79. CHK1 inhibitor will control 50% of cancer tumours via P53 checkpoint.
CHK1 on its own could never be of considerable benefit as works on cell division and replication via mitosis. It may prove well in limiting cancer growth. When used in conjunction with a chemo (which causes cell damage) and the then rapid cell division and reproduction is put into check via the DDR mechanism. Effectively at this point is where the CHK1 inhibitor works and very effectively. However, after periods of treatment some difficult to treat cancers develop CHK1 inhibitor resistance via the utlisation of an alternative pathway or pathways. in addition the cancer can and usually does develop resistance to the chemo as well.

The alternative pathways have been identified and on going studies are being carried out to find non toxic agents with inhibit these pathways.

There are several drugs available that appear at first to be compatible with CHK1. SRA737 is far superior to Prexasertib which is a CHk1 Chk2 inhibitor with regards to safety profile.

The CRT I feel will be more than happy to continue development of CCT245737 in combination with the most suitable alternative pathway inhibitors once back in their possession.

With regard to CTA and without going into semantics too much. I will conclude from the RNS that the MHRA is just a matter of additional supportive information. Cannot see anything to suggest complete resubmission. the use of the term 'not been able to approve' would point to at a later period in time are able. A very slight deviation from not able.
'Not able to' would indicate future decision. 'Not been able' would indicate the past and therefore 'able to; in the future' becomes a distinct possibility.

I find it rather odd that Sareum use the word 'resubmission' before they have discovered exactly what is needed.
Resubmission would imply failure to approve. In this case a formal letter stating 'non approval' would be required before a resubmission can take place.

My take is that Sareum have received a communication from MHRA requesting further supportive evidence and Sareum have panicked. Understandable if they believe they have put together a robust package.

The communication received would be the initial assessment. Then there is the subsequent request for further information which is then followed by a 14 day period in which to respond ( appliction for extension of this available) ,the aim of the MHRA is to give a final decision within 10 days of receipt of reply to request for RFI.

This is where we sit. However, we can also look it in the lines of, should Sareum not obtain the supportive evidence requested then that leaves two options. Review By GLP authority or final decision of non approval.

Should Sareum not be able able within the agreed extension of a timeframe with the MHRA, then I can see this as possibly voiding all preclinical data.

I dont see this happening

Regards

Celtic007 no need for alarm but understand your concern
All that has happened is a request for supportive evidence. No indication of a complete resubmission required.

However, if Sareum cannot produce the required supportive evidence then it will be a requirement of a review by the GLP authority.

I have no idea how long this would take. but most unlikely for a final outcome decision by end of year.

I will lean to the optimistic side and state I believe a CTA approval will be reached by end of year subject to no request for an extension to the 14 day period.

Regards

With regards to CTA I believe where we sit can be shown in the box chart in the below link.

Scroll down and look at the MHRA and REC meetings which from the chart coincide at the same time.

Request for further information is where we sit at the moment. Over half of CTA applicants are requested for further info.

14 days is the timelin but can be extended

In light of the recently released RNS by Sareum I would guess they will not release an RNS stating the submitting of further information, but on the contrary release the final outcome result in an RNS. At the absolute earliest would expect an RNS this Friday and most likely by the end of the following week

https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/phase-1-clinical-trials/#:~:text=Following%20feedback%20from%20our%20research%20community%2C%20applicants%20undertaking

Star786, Aurora although good in preclinical was unable to produce the compound in sufficient amounts to maintain oral bioavailability.
There was problems early days of producing our SDC in sufficient volumes and has since been resolved. In addition in other similar inhibitors resistance to the drug has also been noted.

Chk1 should benefit greatly on its return to CRT. It will mean development can continue with SRA737 as opposed to Prexaterb which was withdrawn duu to toxicity issues. Sareum have never experienced problematic toxicity in any of their compounds.

It will take time and should new drug candidates be formulated to counteract the resistance to CHK1 inhibition then all well and good. Combo with gemcitibine shows favourable results in clinical but at the same time 737 in in vivo preclinical studiea with gemcitabine and PD-! inhibitor was a gargantuan leap forward in efficacy.

Effectively with a time frame you are looking at minimum of 2 years to develop lead candidate in this area.

No reason however that CHK1 and gemcitabine can be used in areas where ther is an unmet need.

Regards

Cobradan I have no objection to differing views. Reasoned argument is the way forward.

The post in itself with its contents whether intended or not was removed.

That says it all.

Epic drivel you put, I will say no more.

Then explain why your posting was removed cobradan or at least your views behind it. I had no involvement of removal of your post. Clearly your post was inappropriate.

Regards

Yes Cobradan you are one to talk. I am not ousting anyone, There are some recent posters who appear to take great delight in undermining others. Do you not remember your post that was removed both insulting and undermining.
'polish a turd'
i suggest you take your own advice or filter me preferably both.

regards

Sneckieboy in what capacity are you to judge whether l know what l am talking about. I put to you a couple of simple questions a short while a go which l will post later just to jog your memory. One thing l can conclude with a degree of accuracy is a lack of education with a rather unhealthy dose of ignorance. I don't know whether to feel sorry for people like you or not?

What are the advantages of signalling through the JH2 domain? Does Tyk 2 Jak 1 inhibit IL-15.

Why in your opinion and with reasons has BMS passed trials in Psoriasis but failed in Ulcerative colitus?

What is the risk now to large pharma with regards to investigations of falsified or non compliantly storing data?

I copy and post some times as easier to put down plus you get imbeciles that want proof of where is this information.

If you behave yourself mummy and daddy might take you out later and buy you an ice cream and let you stay up past 9 0 clock.

Have a good day ho ho ho.

CoL. Good morning. For somebody that wishes to appear so balanced why have you made such a bold statement about my as you term insult. I have not insulted you and if you deem that l have then you indeed are very delicate.
I were insulted by Cobradan post of which you claim not to have seen. With a balanced view you should look at both sides but you deliberately chose not to.

You have an agenda l believe. You are not a long term holder but you make out you are.

Why would you be interested in the sareum compounds that made up from the 28 molecules.

I would suggest you substitute circle for for pond.you are a freak. What sex are you today and please be careful you do not get too much tarmac stuck to the side of your face.

Not the most recent of developments regarding SRA737 but still pertinent.

Study co-leader Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"Our new study establishes the basis for a potentially exciting new approach to treatment involving a two-pronged attack on cancer. We found that doubling up on drugs that target the systems for repairing DNA could be effective even against cancers that do not respond to single-drug treatment.

"Our findings also provide us with a way of picking out which patients are most likely to benefit from existing CHK1 inhibitors like SRA737 - a highly innovative drug discovered at the ICR and currently in clinical development.

"At the ICR, we believe that combinations of targeted drugs will be critical as we aim to overcome the major challenge of cancer evolution and drug resistance - just as they have been in other diseases such as HIV."

Study co-leader Professor Michelle Garrett, previously a Team Leader at The Institute of Cancer Research, London, and currently Professor of Cancer Therapeutics at the University of Kent, said:

"Our study shows the potential of targeting DNA replication for adding to the effect of an existing drug that blocks a system that helps respond to DNA damage.

"It's exciting too that detecting tumours with low levels of B-family DNA polymerases could be used to identify patients most likely to respond to a CHK1 inhibitor, presumably because of natural weaknesses in DNA repair within these cancers.

"The next step is to develop new drug candidates that could be used to target B-family DNA polymerases in combination with the CHK1 inhibitor SRA737, as we have shown that this could open up a potential new therapeutic approach.

Time consuming, but perhaps a big maybe Sareum would become involved in new candidate development funds permitting. A long way off but viable.
Regards

CoL I do note that Cobradans post was removed, so clearly it is not ony me who found it insulting. At least have the decency if you have any to acknowledge this fact.
I bare Cobradan no malice and at times I acknowledge he has made credible input.
Regards

CoL i find your posts just as condescending as Cobradans posts insulting.

There is much research undertaken with CHK1 inhibition resistance post cessation of development by SO.
Far more potential dare I say exists with respect to this aspect.
Our 1802 is a compatible supportive treatment for resistance to CHK1 inhibition and LDG.
Now that 737 will be returning and with CRT involvement especially by Professor Garrett then watch this space. It was after all her baby from the start.
Phase 3 trials with LDG ought not to prove a problem as 737 been well tested in this area. indeed it was patented by SO. far more effective however when used with other inhibitors. Immuno inhibitors were planned in preclinical combo with 737 by SO.

As far as Sareum are concerned the only input I can see is combo with SDC1802 or LDG and 1802.

Plenty of relevant information around on this if you dig deep enough.

Regards

Great comms. You have had a whinge of heart. I were praising 737 yesterday and all you say it is like polishing a turd. You need a good 5hit l think and clean your head out
T..t